Image For Activity Cover
GREQH2MG2402 - CME/CMLE - Pan-tumor HER2 Twitter Chat: HER2 Testing in Various Solid Tumors
Course Description

Pan-tumor HER2 Twitter Chat: HER2 Testing in Various Solid Tumors Cancers  

Activity Overview  

This activity is designed to help pathologists, laboratory professionals, and other members of the cancer care team gain an understanding of the latest evidence regarding HER2 testing in various types of advanced solid tumors. Different testing methods may be used to detect HER2 overexpression, HER2 amplification, and HER2 mutations.  

Target Audience  

This activity has been designed to meet the educational needs of pathologists, laboratory professionals, and other members of the cancer care team.    

Activity Agenda  

  • Introductions 
  • Testing methods 
  • Clinical implications  
  • Practical considerations 
  • Wrap up 

Faculty/Authors

Marilyn M. Bui, MD, PhD, FCAP
Professor and Senior Member in the Department of Pathology at Moffitt Cancer Center 

Swikrity U Baskota,MD, FCAP
Assistant Professor in the Department of Pathology and Laboratory Medicine
University of California Davis Health System 

Laura J. Tafe, MD 
Associate Professor of Pathology and Laboratory Medicine at Dartmouth-Hitchcock Medical Center 

Shu Garcia, MD 
Resident Pathologist at Northwestern University 

Meredith Herman, DO 
Resident Pathologist at the University of Michigan 

Physician's Competency: Patient Care, Medical Knowledge, Practice-Based Learning and Improvement  

CME/CMLE Credit: 1.0
Estimated Completion Time: 1.0 hour
Format: Online educational activity

Credit Designation Statement

The ASCP designates this internet live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.  

ASCP designates this live activity for a maximum of 1.0 CMLE credit.  This activity meets CMP and state re-licensure requirements for laboratory personnel.  

For questions regarding CME credit, please contact ASCP Customer Service at 1-800-267-2727, option 2, in the US & Canada or internationally at access code + 3-1-312-541-4890. Monday-Friday, 8am-5pm CT. 

Method of Participation
To complete the activity and receive credit, the participant must attend the live activity. CME certificates will be provided on-line. 
 
Commercial Support

This activity is supported by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc. 

.
Instructions

To claim CME/CMLE credit for the exercise, do the following:

  1. Review the Technical Considerations.
  2. Click Go to Content to view an overview of the modules in this course.
  3. Complete the Demographic Survey.
  4. Submit the course Evaluation.
  5. Enter the maximum number of credits offered and click Claim CME/CMLE to register credit.

Faculty Disclosures 

Technical Considerations 

Release Dates:  9/26/2024 
Review Date:
Expiration Date: 10/25/2024 




Course Objectives

Upon completion of this activity, you will be able to:

  • Identify when HER2 testing may be indicated in patients with advanced solid tumors 

  • Describe how the use of certain HER2-directed therapy may impact clinical outcomes in patients with advanced solid tumors based on HER testing results 

  • Outline how HER2 testing may be performed in different types of advanced solid tumors 

Summary
Availability: On-Demand
Credit Offered:
1 CME/CMLE Credit
Contains: 2 Courses
Powered By